Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-01-04
2011-01-04
Swartz, Rodney P. (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C424S009100, C424S009200, C424S184100, C435S243000, C435S252100, C514S04400A
Reexamination Certificate
active
07863434
ABSTRACT:
The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with ehrlichiosis; therapeutic uses, specifically vaccines comprising S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins or polypeptides or nucleic acids; and methods of preventing or inhibiting ehrlichiosis in an animal.
REFERENCES:
patent: 5976860 (1999-11-01), Coughlin et al.
patent: 6207169 (2001-03-01), Reed et al.
patent: 6231869 (2001-05-01), Reed et al.
patent: 6277381 (2001-08-01), Reed et al.
patent: 6284238 (2001-09-01), Coughlin et al.
patent: 6306394 (2001-10-01), Murphy et al.
patent: 6306402 (2001-10-01), Reed et al.
patent: 6204252 (2010-03-01), Murphy et al.
patent: WO 96/39484 (1996-12-01), None
patent: WO 97/45540 (1997-12-01), None
patent: WO 98/14584 (1998-04-01), None
patent: WO 98/42740 (1998-10-01), None
patent: WO 00/00615 (2000-01-01), None
patent: WO 00/06744 (2000-02-01), None
Anacker et al., 1987, “Neutralizing Activity of Monoclonal Antibodies to Heat-Sensitive and Heat-Resistant Epitopes ofRickettsia rickettsiiSurface Proteins”, Infect. Immun. 55:825-827.
Chen et al., 1994, “Identification of a GranulocytotropicEhrlichiaSpecies as the Etiologic Agent of Human Disease”, J. Clin. Microbiol. 32:589-595.
Coughlin et al., 1995, “Protection of Dogs from Lyme Disease with a Vaccine Containing Outer Surface Protein (Osp) A OspB, and the Saponin Adjuvant QS21”, J. Infect. Dis. 171:1049-1052.
Dasch et al., 1984, “Approaches to Subunit Vaccines Against the Typhus RickettsiaeRickettsia typhiiandRickettsia prowazekii”, in Microbiology, D. Schlessinger, ed., American Society for Microbiology, Washington, D.C., pp. 251-256.
Dumler et al., 1995, “Serologic Cross-Reactions AmongEhrlichia equi, Ehrlichia phagocytophila, and Human Granulocytic Ehrlichia”, J. Clin. Microbiol. 33:1098-1103.
Dumler et al., 1991, “Identification of Ehrlichia in Human Tissue”, N. Engl. J. Med. 325:1109-1110.
Eremeeva et al., 1994, “Differentiation Among Spotted Fever Group Rickettsiae Species by Analysis of Restriction Fragment Length Polymorphism of PCR-Amplified DNA”, J. Clin. Microbiol. 32:803-810.
Goodman et al., 1996, “Direct Cultivation of the Causative Agent of Human Granulocytic Ehrlichiosis”, N. Engl. J. Med. 334:209-215.
Mahan et al., 1994, “Molecular Cloning of a Gene Encoding the Immunogenic 21 kDa Protein ofCowdria ruminantiurn”, Microbiol. 140:2135-2142.
Palmer et al., 1994, “The ImmunoprotectiveAnaplasma marginaleMajor Surface Protein 2 is Encoded by a Polymorphic Multigene Family”, Infect. Immun. 62:3808-3816.
Ristic and Huxsoll, 1984, “Tribe II. Ehrlichieae Philip 1957, 948AL”, Bergey's Manual of Systemic Bacteriology, vol. 1, Krieg et al. Eds., Williams & Wilkins, pp. 704-709.
Spencer et al., 1984, “Nucleotide Sequence of thesucBGene Encoding the Dihydrolipoamide Succinyltransferase ofEscherichia coliK12 and Homology with the Corresponding Acetyltransferase”, Eur. J. Biochem. 141:361-374.
Sumner et al., 1995, “Protection of Guinea-Pigs from Experimental Rocky Mountain Spotted Fever by Immunization with Baculovirus-ExpressedRickettsia rickettsiirOmpA Protein”, Vaccine 13:29-35.
Tebele et al., 1991, “Induction of Protective Immunity by UsingAnaplasma marginaleInitial Body Membranes”, Infect. Immun. 59:3199-3204.
VanVliet et al., 1994, “Molecular Cloning, Sequence Analysis,and Expression of the Gene Encoding the Immunodominant 32-Kilodalton Protein ofCowdria ruminantium”, Infect. Immun. 62:1451-1456.
Wren, 1991, “A Family of Clostridial and Streptococcal Ligand-Binding Proteins with Conserved C-Terminal Repeat Sequences”, Microbiol. 5:797-803.
Yu et al., 1996, “The Recombinant 120-Kilodalton Protein ofEhrlichia chaffeensis, a Potential Diagnostic Tool”, J. Clin. Microbiol. 34:2853-2855.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 8 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 9 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 10 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 11 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 12 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 13 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 14 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 23 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 24 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 25 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 26 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 27 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 28 in U.S. Patent No. 6,231,869.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 8 in U.S. Patent No. 6,231,869, 2007.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 9 in U.S. Patent No. 6,231,869, 2007.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 10 in U.S. Patent No. 6,231,869, 2007.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 11 in U.S. Patent No. 6,231,869, 2007.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 12 in U.S. Patent No. 6,231,869, 2007.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 13 in U.S. Patent No. 6,231,869, 2007.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 14 in U.S. Patent No. 6,231,869, 2007.
BLAST comparison of Seq ID Nos. 4, 6, 2, 8, 21, 22, 39, 27, 29 and 30 in U.S. Appl. No. 09/792,957 with Seq ID No. 23 in U.S. Patent No. 6,231,869, 2007.
BLA
Beltz Gerald A.
Coughlin Richard T.
Murphy Cheryl
Storey James
Antigenics Inc.
Jones Day
Swartz Rodney P.
LandOfFree
Characterization of granulocytic Ehrlichia and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Characterization of granulocytic Ehrlichia and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Characterization of granulocytic Ehrlichia and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2727684